Many adults notice shifts in energy levels, appetite, and weight patterns over time
It's a common question, especially with newer medications becoming available
Both ultimately raise endogenous growth hormone and IGF-1 levels, placing them mechanistically closer to Tesamorelin than to AOD-9604, which was specifically designed to avoid GH/IGF-1 involvement altogether
At AgeRejuvenation, we treat those underlying drivers so the effort you are already putting in finally shows on the scale and in your body composition
Despite these limitations, phenotype-based treatment holds substantial potential for improving patient outcomes by increasing treatment efficacy, sustainability of weight loss, and optimized use of pharmacotherapy